Influence of dichloromethylene bisphosphonate on the in vitro phagocytosis of hydroxyapatite particles by rat peritoneal exudate cells: an electron microscopic and chemiluminescence study

P M Hyvönen, M J Kowolik

Abstract
Transmission electron microscopy and standard chemiluminescence assays were used to investigate the in vivo effect of dichloromethylene bisphosphonate (clodronate) on the phagocytosis of pure hydroxyapatite particles by rat peritoneal macrophages and the production of chemiluminescence by the peritoneal exudate cells. Hydroxyapatite (control) and a hydroxyapatite/clodronate suspension (28 μmol clodronate per gram of hydroxyapatite, experimental) were injected into the peritoneum of rats, the clodronate dose being 10 μg/kg. Macrophages were harvested at 12, 24, 48, and 96 hours after injection and the particle phagocytosis was assessed by transmission electron microscopy. Hydroxyapatite alone was completely phagocytosed by 24 hours and hydroxyapatite reacted with clodronate was completely phagocytosed by 48 hours. From 48 hours onwards hydroxyapatite particle dissolution was observed in the phagosomes of cells in the two groups. At 48 hours the chemiluminescence produced by the peritoneal exudate cells was also measured. Clodronate and clodronate/hydroxyapatite enhanced cell activity on subsequent challenge with phorbol myristate acetate or zymosan. Clodronate seemed to exhibit an inhibitory effect on the phagocytic activity and an enhancement of the chemiluminescence production by the cells in this model, indicating that it was modifying the inflammatory cell response.

Geminal bisphosphonates are a group of drugs of particular interest because of their ability to modify calcium metabolism. This effect results from a decrease in the solubility of hydroxyapatite in vivo and by cell mediated mechanisms in vivo.1 2 In clinical treatment, bisphosphonates have been used to treat metastatic bone disease,3 hypercalcaemia due to malignancy,4 5 and Paget's disease.6 At the cellular level, the mode of action is not fully understood, but it is known that one of the target cells is the osteoclast, towards which dichloromethylene bisphosphonate (clodronate), at least, is toxic.2 Clodronate is highly soluble in water and shows a strong affinity for calcified tissue.7 In an attempt to clarify the pharmacological mechanisms operating, a number of experimental models have been used.8 It has been shown in an in vivo experiment that clodronate also has anti-inflammatory properties.9

Hydroxyapatite crystals have been found in the joint effusions of patients with rheumatoid arthritis,10 and macrophages remove these crystals from the joint cavities.11 Macrophages, in general, are immunoregulatory and inflammatory cells, the latter function being characterised by their phagocytic capacity. Phagocytosis is the primordial function of neutrophil granulocytes and the two cell types comprise the host's phagocytes. They have been found in the peritoneal cell exudate of many laboratory animals.12 The membrane stimulation of inflammatory phagocytes can be measured by chemiluminescence, that is, the light generated by the oxygen dependent microbicidal system. The chemiluminescence assay is a measure of the rate of liberation of reactive oxygen species by macrophages and granulocytes; these reactive oxygen species may contribute to tissue damage in inflammatory diseases.13 Different pathways of light production can be identified: the myeloperoxide mediated reaction can be identified by stimulating cells with zymosan and using luminol as an intermediate; superoxide anion dependent chemiluminescence can be measured by stimulating cells with phorbol myristate acetate and augmenting the light output with lucigenin.14 Neutrophil granulocytes in most animal species can be strongly activated through these two pathways, whereas monocytes and macrophages have little or no myeloperoxidase.

On the basis of the reports summarised above, we decided to investigate, by transmission electron microscopy, whether the simultaneous presence of clodronate with pure hydroxyapatite particles influences the phagocytosis of these by rat peritoneal macrophages in vivo. We also wanted to see whether, in this experimental system, there would be an effect on the liberation of reactive oxygen species by these cells, as measured by chemiluminescence.

Materials and methods
HYDROXYAPATITE AND CLODRONATE
Chemically pure, synthetically manufactured hydroxyapatite (British Charcoals and MacDonald) with a mean particle size of 5 μm was used.

Clodronate (Leiras Pharmaceuticals) was dissolved in calcium and magnesium free phosphate buffered saline (PBS), pH 7-2, at a working concentration of 2 mg/ml. A hydroxyapatite/clodronate combination was prepared by allow-
ing the two compounds to react in the ratio of 1 g hydroxyapatite to 28 μmol clodronate for a minimum of 42 hours.\(^2\)

**EXPERIMENTAL ANIMALS**

Healthy, adult Wistar SPF rats, in groups of 25 (males, transmission electron microscopy experiments) and 22 (eight males and 14 females, chemiluminescence experiments) animals were used.

**EXPERIMENTAL PROTOCOL**

The peritoneal cavity of each experimental animal was injected according to one of the following protocols: (a) PBS, control group; (b) clodronate alone, drug concentration as above, dose 10 mg/kg body weight; (c) hydroxyapatite suspension alone at 84.55 mg/ml; (d) hydroxyapatite/clodronate combination giving the same concentrations of agents as in b and c. Intraperitoneal incubation was allowed to proceed for 12, 24, 48, 72, or 94 hours.

The chemiluminescence experiments were performed at 48 hours after injection only. In addition, the drug at 30 mg/kg alone and the hydroxyapatite/clodronate combination were tested for their influence on chemiluminescence. The volume injected was consistently 10 mg/kg.

**HARVESTING AND COLLECTION OF PERITONEAL CELLS**

The animals were anaesthetised with 6.1% thiopental solution (Hypnorm, Leiras), the minimum dose being 2 ml. Abdominal skin and muscles were reflected and the peritoneal wall exposed. One catheter (Venflon No 2, Viggo) was inserted into the peritoneal cavity at the groin and another symmetrically on the opposite side. Via one catheter, 20 ml of sterile PBS was injected into the peritoneum and after two minutes of gentle massage the stopper was removed from the opposite catheter. The fluid was allowed to drip into a 50 ml polyethylene tube (Costar No 3350) in ice. PBS was added continuously via the first catheter and a total of 50–100 ml of lavage fluid was collected. This was centrifuged at 380 g for 10 minutes, after which any red blood cells were removed by hypotonic lysis with 0.87% ammonium chloride solution for 10 minutes. After further centrifugation the cells were resuspended in PBS and counted in a Coulter counter prior to the assessment of cell viability by trypan blue dye exclusion.

The animals were killed after cell harvesting by cervical dislocation. All animal procedures were in compliance with the Declaration of Helsinki.

**PREPARATION OF SPECIMENS FOR TRANSMISSION ELECTRON MICROSCOPY**

A cell pellet was formed by centrifugation at 380 g for 10 minutes, and prefixed in 2% glutaraldehyde solution for two hours. The pellet was then washed for 10 minutes in PBS and postfixed in 1% osmium tetroxide for one hour. Thereafter the pellet was washed and dehydrated in increasing concentrations of alcohol and finally in propylene oxide. The specimen was then embedded in epoxy resin (LX-112, Ladd Research Industries) by a standard procedure. Ultrathin sections were cut with an LKB Ultramicrotome and stained with Ultrastain 1 (9001 3710) for 20 minutes and Ultrastain 2 (9001 3711) for two minutes, at room temperature (both stains from LKB). Finally, the specimens were mounted on copper grids, sputtered with carbon and viewed with a Jeol JEM-1200 EX transmission electron microscope.

For each experiment at each time point a minimum of 50 fields was examined to assess cell morphology and phagocytosis.

**MEASUREMENT OF CHEMILUMINESCENCE**

The concentration of cells was adjusted to 1×10⁶ cells per ml for the chemiluminescence experiments.

To test the activation of the superoxide anion pathway, 500 μl of cell suspension was placed in the reaction cuvette, followed by 200 μl lucigenin (1×10⁻³ M, Sigma Chemicals) and 200 μl phorbol myristate acetate as stimulant (2.5 μg/ml, Sigma Chemicals).

The resultant chemiluminescence was measured at 37°C in an LKB 1250 luminometer, recorded as millivolts and calculated per 1×10⁶ cells. From the curves generated the maximum potential was recorded. In addition, the area under the curve was quantitated between the start of the experiment and the point at which the potential had declined to 50% of the peak value. This was achieved by digitising the data from the curves using a Kontron image analysis system (IBAS 1).

To assess any contribution to the production of chemiluminescence by the myeloperoxidase mediated pathway, 200 μl luminol (5×10⁻⁴ M) and 200 μl myeloperoxidase-zymosan (10 mg/ml) were added to the reaction vial.

The two chemiluminescence systems were studied alone and consecutively in the cell batch experiment. For example, luminol and zymosan were added to the reaction cuvette after the chemiluminescence produced by the lucigenin/phorbol myristate acetate regimen had subsided to 50% of the peak potential and vice versa. At least one duplicate experiment was conducted on cells collected from each animal.

**STATISTICAL ANALYSIS**

Student’s t test was used for statistical analysis.

**Results**

Cell viability in the lavage fluid was consistently greater than 96%, as determined by the trypan blue dye exclusion test.

**TRANSMISSION ELECTRON MICROSCOPY**

**EXPERIMENTS**

Phagocytosis and morphology were assessed only for the macrophages. These made up approximately 90% of the exudate cells, the rest of the cells being mainly granulocytes.
Dichloromethylene bisphosphonate phagocytosis of hydroxyapatite

Figure 1 shows that the cells collected from the control animals showed good general morphology and cell organelles.

Effect of clodronate
Initially, the cell morphology seemed to be unaffected by the presence of clodronate. Figure 2A shows that until 24 hours after injection the cells from the control and injected animals looked similar. Figure 2B shows that macrophages collected later showed increasing heterogeneity of the cytoplasm, but mitochondria were seen.

Phagocytosis of hydroxyapatite particles
After 12 hours of incubation there was evidence of intracellular hydroxyapatite, but at this time particles were also regularly observed extra-cellularly. All hydroxyapatite particles had been phagocytosed by 24 hours as none was seen extracellularly. Figure 3 shows that in several 72 and 96 hour specimens disintegration of intravacuolar hydroxyapatite particles was observed. This was accompanied by vacuolisation of the cytoplasm and degeneration of cellular morphology (fig 3B).

Phagocytosis of hydroxyapatite particles reacted with clodronate
Phagocytosis was frequently seen from 12 hours onwards. By 24 hours most but not all hydroxyapatite particles were intracellular, and by 48 hours no particles remained outside the cells. Hydroxyapatite particle disintegration and crystal dissolution were seen only rarely at 48 hours, but in numerous cells in 72 and 96 hour experiments (figs 4A and B). The frequency or extent of particle dissolution was not quantitated. In the presence of phagocytosis, good cell morphology was preserved during the incubation. Figure 4B shows that at 96 hours cytoplasm had degenerated less than in cells containing plain hydroxyapatite, and morphologically distinct mitochondria were seen. The situation was similar at 72 hours. Figure 4C shows an example of more advanced hydroxyapatite particle dissolution at 96 hours.

CHEMILUMINESCENCE EXPERIMENTS
Chemiluminescence assays were performed for the peritoneal exudate cells, which consisted of two cell types capable of light generation: macrophages and polymorphonuclear neutrophil granulocytes.

Pattern of chemiluminescence production
In all experimental systems chemiluminescence was produced, showing cell viability and activation. A total of 45 experiments was conducted, and a minimum of four tests was performed per experimental group. Figures 5–8 show examples of the pattern of chemiluminescence kinetics, the voltage values on the vertical axis being for $5 \times 10^6$ cells.

Figure 5 shows a typical example of phorbol
myristate acetate stimulated, lucigenin augmented chemiluminescence. Figure 6 illustrates that of a zymosan/luminol experiment. A comparison of the two curves shows a faster response in the phorbol myristate acetate/lucigenin system. This pattern of kinetics was also observed in the combination experiments as shown in figs 7 and 8. Similar chemiluminescence curve shapes were obtained in combination experiments with hydroxyapatite/clodronate incubation.

**Effect of clodronate on chemiluminescence**

Table 1 summarises the results obtained for the phorbol myristate acetate/lucigenin system, comparing the influence of clodronate with the PBS control. The chemiluminescence output was similar in terms of potential to the control, but the area under the curve was greater at high clodronate concentrations than the control.

**Effect of hydroxyapatite and hydroxyapatite/clodronate on chemiluminescence**

Table 2 compares assays performed with hydroxyapatite/clodronate using hydroxyapatite as the drug free control and PBS as the apatite free control. The difference between the areas under the curve reflects the difference in curve shape, which in turn denotes a more sustained chemiluminescence response with a higher total energy output.

In addition to the results shown in the tables, there was a significant difference in both the potential and the area under the curve between 10 mg/kg clodronate and 10 mg/kg hydroxyapatite/clodronate (p<0.01).

**Discussion**

The mechanism(s) by which bisphosphonate drugs exert their therapeutic effects in the management of osteolytic bone diseases have been extensively studied, but only partly elucidated. It is now known that, in bone, the osteoclast is the primary biological target of clodronate.\(^2\)\(^\text{15}\)

In this study we have attempted to apply two methods of studying the effects of bisphosphonate on inflammatory cells. This approach was used to aid the understanding of the proposed anti-inflammatory action of clodronate\(^6\) at the cellular level. This drug has been studied extensively and used in treatment for many years and data have accumulated on its effect on hard tissue metastases\(^,\)\(^\text{16}\)\(^\text{17}\), hypercalcaemia due to malignancy\(^,\)\(^\text{4}\)\(^\text{18}\), Paget's disease of bone\(^,\)\(^\text{6}\)\(^\text{8}\), and osteoporosis\(^.\)\(^\text{19}\)

This drug affects not only

**Table 1** Comparison of peak chemiluminescence potential and area under the curve for exudate cells assayed in the phorbol myristate acetate/lucigenin system, n=Number of assays performed in each group. There was no significant difference between the drug and control groups (t test)

<table>
<thead>
<tr>
<th>Clodronate concentration (mg/kg)</th>
<th>Phosphate buffered saline (control)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 (n=4)</td>
<td>30 (n=4)</td>
</tr>
<tr>
<td>Mean (SD) potential per 1×10(^6) cells</td>
<td>0.34 (0.31) 0.38 (0.22) 0.29 (0.10)</td>
</tr>
<tr>
<td>Mean (SD) area under curve per 1×10(^6) cells (mm(^2))</td>
<td>187 (137) 330 (183) 158 (88)</td>
</tr>
</tbody>
</table>

**Table 2** Comparison of peak chemiluminescence potential and area under the curve for exudate cells assayed in the phorbol myristate acetate/lucigenin system in the presence of hydroxyapatite, n=Number of assays performed in each group

<table>
<thead>
<tr>
<th>Clodronate/hydroxyapatite concentration (mg/kg)</th>
<th>Hydroxyapatite (control) at 84.55 mg/ml</th>
<th>Phosphate buffered saline (control)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 (n=4)</td>
<td>30 (n=4)</td>
<td></td>
</tr>
<tr>
<td>Mean (SD) potential per 1×10(^6) cells</td>
<td>1.16 (0.38)* 0.83 (0.45)</td>
<td>0.47 (0.22)* 0.21 (0.10)**</td>
</tr>
<tr>
<td>Mean (SD) area under curve per 1×10(^6) cells (mm(^2))</td>
<td>426 (258)$\dagger$ 508 (173)$\dagger$</td>
<td>407 (258) 158 (80)$\dagger$</td>
</tr>
</tbody>
</table>

*††Significant difference (p<0.05) between marked groups (t test).
†Significant difference (p<0.01) between marked groups (t test).
bone calcium metabolism, but has been shown to have anti-inflammatory properties in an adjuvant arthritis animal model and to inhibit the excretion of lysosomal enzymes in conjunction with parathyroid hormone induced resorption and prostaglandin E₂ in vitro. It was of interest to determine the effect of reacting hydroxyapatite with clodronate on the subsequent phagocytosis of particles, and chemiluminescence production, by rat peritoneal macrophages.

The intracellular location of clodronate, when given to cells in culture in the absence of mineral crystals, appears to be in the cytosol. As clodronate has a high affinity for hydroxyapatite, binding with the mineral could give it...
an effective means of entry into the cell, once the particle is phagocytosed. Its high solubility in water, which prevents it passing through physiological membranes and thus entering the cell in large amounts (only 1–2%, concluded from the kinetic study of Yakatan et al.), may facilitate its intracellular pharmacological action after having gained entry at a higher concentration in combination with the mineral.

When hydroxyapatite particles were pre-incubated with clodronate, phagocytosis was observed less frequently at 12 and 24 hours than for hydroxyapatite particles alone. This finding is in agreement with the impaired attachment of macrophages to bone in the presence of bisphosphonate, observed by Chambers using light microscopy. The hypothesis that the action of clodronate on the macrophage is mediated intracellularly is naturally valid, at least in the presence of hydroxyapatite. The observed delay in phagocytosis of the hydroxyapatite/clodronate particles may be a result of extracellular membrane irritation due to the clodronate bound to the crystal surface. Cellular toxicity has been shown towards the macrophage. The results presented here may be a reflection of similar cytotoxicity. The conclusions are not surprising if these two cells types share a common bone hematopoietic precursor. Minkin and Shapiro have, however, voiced a word of caution about the assumption that peripheral blood monocytes or elicited peritoneal macrophages might be the actual osteoclast precursors.

In considering rheumatoid arthritis, the intracellular activation of macrophages by hydroxyapatite may inadvertently contribute to tissue damage. The anti-inflammatory effect of clodronate may therefore result in macrophages being impaired in their ability to contribute to the destruction of surrounding tissues. In this in vivo model there was no doubt that the cells were able to ingest the hydroxyapatite particles whereby the drug was able to enter the cell. This can also occur in the affected joint in rheumatoid arthritis, where the macrophage is functioning as a scavenger of the crystals and other debris.

Once phagocytosed, crystal degradation and dissolution occurs with time in the phagocytic vacuoles containing both pure hydroxyapatite and hydroxyapatite/clodronate particles. The concentration of clodronate used in this experiment did not significantly alter this lytic activity compared with the clodronate free, crystal containing cells during the observation period. The finding does not conflict with reports of some in vitro studies on mononuclear cells being capable of mineral particle phagocytosis or bone resorption. A fundamental difference between the above mentioned in vitro studies, which have been conducted with powdered bone, and this work is the lack of organic matrix in the hydroxyapatite used. As there is no foreign protein component in the mineral, the cells could regard this substance as non-immunogenic.

Cell morphology showed progressive degeneration with time. This seemed to be more extensive with hydroxyapatite alone than with hydroxyapatite/clodronate. Clodronate is known to be cytotoxic in the presence of calcified material, and yet in this experimental system good cell morphology was preserved. Throughout the study mitochondria were clearly seen in most cells, indicating the potential for metabolism.

The chemiluminescence results support those of the transmission electron microscopy experiments. Firstly, under all in vivo incubation conditions the cells were viable and capable of activation in the standardised chemiluminescence assays, the least activation occurring in the PBS control group. Secondly, the results reinforce the assumption that clodronate gains minimal access to the interior of the cell without hydroxyapatite, but does so in combination with it. Finally, it appeared that incubation with hydroxyapatite and with hydroxyapatite/clodronate enhanced the subsequent response to stimulus, i.e. the incubation had primed the cells, a phenomenon thought to be of considerable importance in biological homeostasis. This effect was seen in the higher peak potential with the hydroxyapatite/clodronate group, denoting a more rapid release of energy by the cells than in the hydroxyapatite group. In contrast, the areas under the curves were similar, suggesting a more sustained response in the hydroxyapatite group. It may be relevant that clodronate is a chlorinated molecule and as
Dichloromethylene bisphosphonate and phagocytosis of hydroxyapatite

such may be able to interact directly with chemiluminescence production. The finding that cell activation occurred in the two chemiluminescence systems suggests that macrophages and neutrophils were present in the exudate; this was supported by light microscopic and transmission electron microscopy examination. The consecutive activation of chemiluminescence pathways in the same cells (figs 7 and 8) is also suggestive of a mixed cell population but, as neutrophils in particular are able to respond strongly through the two systems, the results may also illustrate the high response levels in this exudate. This has been shown previously in human gingival crevicular exudate cells. In this course of the study, neither the earliest stages of phagocytosis nor the late lysis of the hydroxyapatite containing cells was seen. Further studies will be necessary to observe these stages.

This animal model allows the study of some cellular effects of the bisphosphonate drugs in vivo, and thereby facilitates the interpretation of their pharmacological action in relation to bone metabolism and anti-inflammatory function. The hydroxyapatite crystals are taken into the cells, and clodronate thereby gains access to the cell interior, the inflammatory cell function is modified, as indicated by the chemiluminescence assays. These results support the use of clodronate in the clinical management of inflammatory bone and joint diseases.

We are grateful to Aria Korhonen and Pekka Alakuijala for their technical expertise and Eija Voutilainen, Eija Antikainen, and Alpo Pelttari for their assistance and expert advice with the electron microscopic work. The authors also thank Dr A. Naukkarinen for her advice on the interpretation of the transmission electron microscopy photographs. The hydroxyapatite was kindly donated by British Charcoals and McDonald (Greenock, United Kingdom) and the dichloromethylene bisphosphonate by Dr Hansu Hauhijarvi (Leiras Pharmaceuticals, Turku, Finland). Financial support was also provided by Leiras Pharmaceuticals. This study was supported by a grant from the Finnish Cultural Foundation to P M Hyvonen. Our gratitude is expressed.


Influence of dichloromethylene bisphosphonate on the in vitro phagocytosis of hydroxyapatite particles by rat peritoneal exudate cells: an electron microscopic and chemiluminescence study.

P M Hyvönen and M J Kowolik

doi: 10.1136/ard.51.2.203

Updated information and services can be found at:
http://ard.bmj.com/content/51/2/203

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/